<p>Biophytis SA has entered a strategic agreement in Asia and secured $20 million to support the launch of a Phase 3 clinical trial for sarcopenia. This collaboration marks a significant step for Biophytis in advancing its clinical development in the Asian market. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biophytis SA published the original content used to generate this news brief on January 28, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here</p>

SBIO

BPTSY

PMCB

<p>Biophytis SA has secured a $20 million strategic agreement in Asia to support its Phase 3 clinical trial for sarcopenia. This collaboration represents a significant advancement for Biophytis in its clinical development efforts within the Asian market.</p>

Reuters

VanEck Biotech ETF

ALPS Medical Breakthrough

Invesco Biotechnology & Genome ETF

Proshares Ultra Nasdaq Biotech

SPDR S&P Biotech

iShares Biotechnology ETF

First Trust NYSE Arca Biotech Index Fd

Biophytis S.A.

PharmaCyte Biotech

Biophytis Secures $20 Million in Strategic Asia Agreement for Phase 3 Sarcopenia Trial